Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis

World Health Organization. HIV/AIDS. 2021. https://www.who.int/news-room/fact-sheets/detail/hiv-aids. Accessed 20 Sep 2022.

Pilgrim NA, Evans TM, Czarnogorski M. A layer plus approach to implementation research and collaboration for long-acting injectable pre-exposure prophylaxis for HIV prevention. Health Promot Pract. 2022. https://doi.org/10.1177/15248399211053584.

Article  PubMed  Google Scholar 

Durham SH, Milam A, Waer D, et al. Cabotegravir: the first long-acting injectable for HIV preexposure prophylaxis. Ann Pharmacother. 2022. https://doi.org/10.1177/10600280221102532.

Article  PubMed  Google Scholar 

Clement ME, Kofron R, Landovitz RJ. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS. 2020;15(1):19–26.

Article  Google Scholar 

Flexner C. The future of long-acting agents for preexposure prophylaxis. Curr Opin HIV AIDS. 2022;17(4):192–8.

Article  CAS  Google Scholar 

Spinelli MA, Grinsztejn B, Landovitz RJ. Promises and challenges: cabotegravir for preexposure prophylaxis. Curr Opin HIV AIDS. 2022;17(4):186–91.

Article  CAS  Google Scholar 

ViiV Healthcare. APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use: US prescribing information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215499s000lbl.pdf. Accessed 20 Sep 2022.

Markham A. Cabotegravir plus rilpivirine: first approval. Drugs. 2020;80(9):915–22.

Article  CAS  Google Scholar 

Smith RA, Wu VH, Zavala CG, et al. In vitro antiviral activity of cabotegravir against HIV-2. Antimicrob Agents Chemother. 2018;62(10):e01299-e1318.

Article  CAS  Google Scholar 

Andrews CD, Yueh YL, Spreen WR, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med. 2015;7(270):270ra4.

Article  Google Scholar 

Vishwanathan SA, Zhao C, Luthra R, et al. Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques. AIDS. 2022;36(2):169–76.

Article  CAS  Google Scholar 

Dobard C, Makarova N, Nishiura K, et al. Long-acting cabotegravir protects macaques against repeated penile simian-human immunodeficiency virus exposures. J Infect Dis. 2020;222(3):391–5.

Article  CAS  Google Scholar 

Andrews CD, Spreen WR, Mohri H, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151–4.

Article  CAS  Google Scholar 

Andrews CD, Bernard LS, Poon AY, et al. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS. 2017;31(4):461–7.

Article  CAS  Google Scholar 

Yoshinaga T, Seki T, Miki S, et al. Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors. Antiviral Res. 2018;152:1–9.

Article  CAS  Google Scholar 

Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595–608.

Article  CAS  Google Scholar 

Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779–89.

Article  CAS  Google Scholar 

Smith SJ, Zhao XZ, Burke TR Jr, et al. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15(1):37.

Article  Google Scholar 

Han K, Wannamaker P, Lu H, et al. Safety, tolerability, pharmacokinetics, and acceptability of oral and long-acting cabotegravir in HIV-negative Chinese men. Antimicrob Agents Chemother. 2022;66(3):e0205721.

Article  Google Scholar 

Landovitz RJ, Li S, Eron JJ Jr, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472–81.

Article  Google Scholar 

Yu Y, Bigos KL, Marzinke MA, et al. A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP. Br J Clin Pharmacol. 2022;88(10):4623–32.

Article  CAS  Google Scholar 

Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–40.

Article  Google Scholar 

Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15(11): e1002690.

Article  Google Scholar 

Marzinke MA, Grinsztejn B, Fogel JM, et al. Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021;224(9):1581–92.

Article  CAS  Google Scholar 

Grinsztejn B, Hanscom B, Wang Z, et al. Transgender women (TGW) in HPTN 083: an evaluation of safety, efficacy, and gender affirming hormonal therapy (GAHT) interactions with long-acting cabotegravir (CAB-LA) [abstract no. 12707 plus poster]. In: The 24th International AIDS Conference. 2022.

Landovitz RJ, Donnell D, Tran H, et al. Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs TDF/FTC for PrEP [abstract no. 96]. In: Conference on Retroviruses and Opportunistic Infections. 2022.

Psaros C, Landovitz RJ, Rice W, et al. Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators and preferences for PrEP use among MSM and TGW [abstract no. OALC0503]. J Int AIDS Soc. 2021;24(Suppl 4):30.

Google Scholar 

Eshleman SH, Fogel JM, Piwowar-Manning E, et al. Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084. J Infect Dis. 2022;225(10):1741–9.

Article  CAS  Google Scholar 

Delany-Moretlwe S, Hughes JP, Bock P, et al. Long acting cabotegravir: updated efficacy and safety results from HPTN 084 [abstract no. 13063]. In: The 24th International AIDS Conference. 2022.

Tolley E, Bula A, Chitukuta M, et al. Acceptability of injectable cabotegravir versus daily oral TDF/FTC for PrEP: lesson from HPTN 084 [abstract no. 8961 plus poster]. In: The 24th International AIDS Conference. 2022.

US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States: 2021 update. 2021. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Accessed 20 Sep 2022.

Celum C, Baeten J. PrEP for HIV prevention: evidence, global scale-up, and emerging options. Cell Host Microbe. 2020;27(4):502–6.

Article  CAS  Google Scholar 

Sugarman J, Donnell DJ, Hanscom B, et al. Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial. Lancet HIV. 2021;8(11):e723–8.

Article  Google Scholar 

US National Institutes of Health. ClinicalTrials identifier NCT04692077. 2020. https://clinicaltrials.gov. Accessed 20 Sep 2022.

US National Institutes of Health. ClinicalTrials identifier NCT04824131. 2021. https://clinicaltrials.gov. Accessed 20 Sep 2022.

Meyers K, Rodriguez K, Brill AL, et al. Lessons for patient education around long-acting injectable PrEP: findings from a mixed-method study of phase II trial participants. AIDS Behav. 2018;22(4):1209–16.

Article  Google Scholar 

Levy ME, Agopian A, Magnus M, et al. Is long-acting injectable cabotegravir likely to expand PrEP coverage among MSM in the District of Columbia? J Acquir Immune Defic Syndr. 2021;86(3):e80–2.

Article  Google Scholar 

Irie WC, Calabrese SK, Patel RR, et al. Preferences for HIV preexposure prophylaxis products among Black women in the U.S. AIDS Behav. 2022;26(7):2212–23.

Article  Google Scholar 

Cohen MS, Landovitz RJ. Assessing the role of long-acting cabotegravir preexposure prophylaxis of human immunodeficiency virus: opportunities and aspirations. J Infect Dis. 2021;223(1):1–3.

Article  CAS  Google Scholar 

Schmidt HA, Rodolph M, Schaefer R, et al. Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice. J Int AIDS Soc. 2022;25(7): e25963.

Article  CAS  Google Scholar 

Wray TB, Chan PA, Klausner JD, et al. Gay, bisexual, and other men who have sex with men who are not on oral PrEP may be less interested in available injectable products than in oral PrEP: examining individual-level determinants of interest and barriers across products. AIDS Behav. 2022. https://doi.org/10.1007/s10461-022-03708-3.

Article  PubMed  Google Scholar 

Rael CT, Lopez-Ríos J, McKenna SA, et al. Transgender women’s barriers, facilitators, and preferences on tailored injection delivery strategies to administer long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP). AIDS Behav. 2021;25(12):4180–92.

Article  Google Scholar 

Rael CT, Martinez M, Giguere R, et al. Transgender women’s concerns and preferences on potential future long-acting biomedical HIV prevention strategies: the case of injections and implanted medication delivery devices (IMDDs). AIDS Behav. 2020;24(5):1452–62.

Article  Google Scholar 

Conniff J, Evensen A. Preexposure prophylaxis (PrEP) for HIV prevention: the primary care perspective. J Am Board Fam Med. 2016;29(1):143–51.

Article  Google Scholar 

Sharfstein JM, Killelea A, Dangerfield D. Long-acting cabotegravir for HIV prevention: issues of access, cost, and equity. JAMA. 2022;327(10):921–2.

Article  CAS  Google Scholar 

Jamieson L, Johnson LF. The relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis: a modelled economic evaluation and threshold analysis in South Africa based on the HPTN 083 and 084 trials. Lancet. 2022. https://doi.org/10.2139/ssrn.4047136.

Article  Google Scholar 

Joob B, Wiwanikit V. Changing from tenofovir/emtricitabine to cabotegravir for pre exposure prophylaxis for HIV in men who have sex with men: a cost utility analysis from an endemic country. J Assoc Physicians India. 2022;70(2):11–2.

PubMed  Google Scholar 

Neilan AM, Landovitz RJ, Le MH, et al. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis. Ann Intern Med. 2022;175(4):479–89.

Article  Google Scholar 

留言 (0)

沒有登入
gif